Companies › Aribio Lab
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease, Vaccines; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CVI-VZV-001 Herpes zoster vaccine | – | Phase 2 | Herpes Zoster; Vaccine-Preventable Diseases | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06137755 | CVI-VZV-001 | Phase 1 | Vaccine-Preventable Diseases | Vaccines | Jan 2025 |
| NCT07481604 | CVI-VZV-001 | Phase 2 | Herpes Zoster | Infectious disease | Jan 2027 |
No annotated target.
–
Guangzhou Patronus Biotech Dynavax Technologies Cellid Green Cross Osivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.